Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

2016 ◽  
Vol 27 (7) ◽  
pp. 695-701 ◽  
Author(s):  
Per Kongsted ◽  
Inge M. Svane ◽  
Henriette Lindberg ◽  
Rasmus Bisbjerg ◽  
Gedske Daugaard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Second Line ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy

2016 ◽  
Vol 13 (1) ◽  
pp. 22-28 ◽  
Author(s):  
Christoph A. von Klot ◽  
Markus A. Kuczyk ◽  
Alena Boeker ◽  
Christoph Reuter ◽  
Florian Imkamp ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Free Testosterone ◽  
Second Line ◽  
Castration Resistant Prostate Cancer ◽  
Second Line Therapy ◽  
Testosterone Levels ◽  
Castration Resistant ◽  
Line Therapy

scholarly journals SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES

2018 ◽  
Vol 14 (3) ◽  
pp. 120-127 ◽  
Author(s):  
A. S. Markova ◽  
V. B. Matveev ◽  
B. M. Nazranov
Keyword(s):  
Prostate Cancer ◽  
Sequential Therapy ◽  
Therapeutic Agents ◽  
Continuous Treatment ◽  
Castration Resistant Prostate Cancer ◽  
Treatment Standards ◽  
Factors Affecting ◽  
Castration Resistant ◽  
Line Therapy ◽  
Significant Factors

Currently, doctors have at their disposal a number of drugs prolonging life of patients with castration-resistant prostate cancer (CRPC). The majority is approved for use as the 1st line therapy and, in absence of direct comparison, is considered potentially equally effective. Patients with CRPC need continuous treatment for suppression of disease progression resulting in sequential use of therapeutic agents. Modern standards and recommendations do not provide a clear algorithm for prescription, therefore an individual approach is necessary taking in account various factors of a particular case ranging from previous therapies to patients’ preferences. This article considers the most significant factors affecting CRPC therapy selection and ways of therapy optimization in compliance with the established treatment standards and taking into account the list of drugs approved for use in Russia.

Sign in / Sign up

Export Citation Format

Share Document